Document is current
Any future updates will be listed below
-
Authors
Hahn, Andreas https://orcid.org/0000-0001-9727-7580
Reed, Murray B.
Murgaš, Matej
Vraka, Chrysoula
Klug, Sebastian https://orcid.org/0000-0001-8714-6608
Schmidt, Clemens https://orcid.org/0000-0003-3138-6869
Godbersen, Godber M. https://orcid.org/0000-0002-9739-0724
Eggerstorfer, Benjamin https://orcid.org/0000-0002-3400-2181
Gomola, David
Silberbauer, Leo R. https://orcid.org/0000-0002-8521-1012
Nics, Lukas
Philippe, Cécile https://orcid.org/0000-0002-7203-7174
Hacker, Marcus https://orcid.org/0000-0002-4222-4083
Lanzenberger, Rupert https://orcid.org/0000-0003-4641-9539
-
Funding
Funding for this research was provided by:
Vienna Science and Technology Fund (DOI: 10.47379/CS18039)
Austrian Science Fund (DOI: 10.55776/KLI1006)
Austrian Science Fund (DOI: 10.55776/KLI610)
- License Information
-
More Information
Article History
Received: 9 February 2024
Revised: 26 July 2024
Accepted: 12 August 2024
First Online: 23 August 2024
Competing interests
: RL received investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. M. Hacker received consulting fees and/or honoraria from Bayer Healthcare BMS, Eli Lilly, EZAG, GE Healthcare, Ipsen, ITM, Janssen, Roche, and Siemens Healthineers. All other authors report no conflict of interest in relation to this study.
